Skip to content
How It Works
Explore
Ask a Question Resources Pricing
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 31 peer-reviewed journal articles Updated
Nephrology

Organ Involvement: Kidneys, Lungs, Heart, Skin, and Eyes

At a Glance

Tuberous sclerosis complex can affect several organs, so lifelong monitoring is important. Kidney AMLs, lung LAM, heart rhabdomyomas, skin lesions, and retinal hamartomas each have specific screening and treatment options based on age, symptoms, growth, and organ function.

Because Tuberous Sclerosis Complex (TSC) can affect almost any organ system, management requires a “whole-body” approach. While the brain is often the primary focus, monitoring the kidneys, lungs, heart, skin, and eyes is essential for long-term health. Most growths in these organs are non-cancerous (hamartomas), but they can still cause symptoms by growing or pressing on healthy tissue [1][2].

Kidney Involvement: AMLs and Cysts

The kidneys are the most common organ affected outside the brain, with up to 80% of people with TSC developing kidney features [3].

  • Angiomyolipomas (AMLs): These are non-cancerous tumors made of blood vessels, muscle, and fat. They are the most common kidney finding in TSC [4].
  • Renal Cysts: These are fluid-filled sacs. While common, some patients have a rare “contiguous gene syndrome” where both the TSC2 and PKD1 (polycystic kidney disease) genes are affected, leading to many cysts and early kidney challenges [5].

Management and Treatment

Doctors prefer using abdominal MRI over ultrasound to detect and characterize kidney lesions, monitoring them every 1–3 years [6]. Importantly, surveillance also requires routine checking of kidney function (eGFR), testing for protein in the urine, and annual blood pressure monitoring.

  • Treatment Considerations: Current guidance generally favors systemic mTOR inhibitors (like everolimus) for asymptomatic, actively growing AMLs larger than 3 cm. This is not an automatic trigger; treatment decisions factor in growth rate, aneurysms, bleeding risk, kidney function, and reproductive plans [7][8].
  • Bleeding Emergencies: Because AMLs have many blood vessels, they can occasionally bleed. If this happens, a procedure called selective arterial embolization is used to block blood flow to the tumor and stop the hemorrhage [9][10].
  • Surgery: Doctors try to avoid removing the whole kidney. If surgery is needed, they prefer “nephron-sparing” approaches that remove only the tumor [11].

Lung Involvement: LAM

Lymphangioleiomyomatosis (LAM) is a lung condition where muscle-like cells grow uncontrollably in the lungs, creating thin-walled cysts [12]. It primarily affects adult women with TSC [13].

  • Symptoms: Many women have no symptoms initially, but some may experience shortness of breath (dyspnea), chest pain, or a collapsed lung (pneumothorax) [14]. Patients should be counseled about pneumothorax risks, estrogen exposure, and pregnancy considerations.
  • Diagnosis and Screening: Women should receive a baseline high-resolution chest CT in late adolescence or early adulthood. Follow-up depends on whether cysts are present. A blood test called VEGF-D is useful (levels ≥800 pg/mL are highly specific), but a normal result does not exclude LAM [15][16]. Pulmonary function testing (PFTs) is central to monitoring lung impairment over time.
  • Treatment: If lung function begins to decline, sirolimus is the best-established systemic mTOR therapy for clinically significant TSC-LAM, and is very effective at stabilizing the disease [17][18].

Heart Involvement: Cardiac Rhabdomyomas

These are heart tumors that often appear before birth or shortly after [19].

  • Natural History: Most of these tumors shrink significantly or disappear entirely on their own during the first two years of life [20][21].
  • When Treatment is Needed: If a tumor is very large and blocks blood flow or causes dangerous heart rhythms (arrhythmias), doctors may use an mTOR inhibitor to shrink it quickly [22][23]. Surgery is rarely needed and reserved for life-threatening cases [24].

Skin, Eye, and Other Manifestations

Skin signs are often the first clue that someone has TSC, appearing in over 90% of patients [1].

Skin Treatments

  • Facial Angiofibromas: These small, reddish bumps on the face can be treated with topical sirolimus (a cream or gel). Studies show it significantly reduces the size and redness of the lesions [25][26].
  • Other Lesions: Other features include white spots (hypomelanotic macules), leathery patches (shagreen patches), and growths under the nails (ungual fibromas) [27]. These are mostly managed for comfort or appearance using lasers or minor surgery [28]. Dental enamel pits are also common, so routine dental care is important.

Eye Health

  • Retinal Hamartomas: These are “freckle-like” growths on the back of the eye (the retina). They are usually harmless and do not affect vision [29].
  • Monitoring: Even though they rarely cause problems, regular dilated eye exams are important to check for any unusual changes or rare complications like fluid buildup, although they may not need to be strictly annual if lesions are stable [30][31].

Common questions in this guide

How often should kidney monitoring be done in tuberous sclerosis complex?
Kidney monitoring commonly includes an abdominal MRI every 1–3 years, a blood test called eGFR that estimates kidney function, urine protein checks, and yearly blood pressure measurement. The schedule may change based on kidney lesions, their growth, and overall kidney function.
When does a kidney AML in TSC need treatment?
An asymptomatic AML that is actively growing and larger than 3 cm may be considered for a systemic mTOR medicine such as everolimus. Size alone does not automatically require treatment; clinicians also consider aneurysms, bleeding risk, kidney function, and reproductive plans.
What screening is recommended for LAM in women with TSC?
Women with TSC are generally offered a baseline high-resolution chest CT in late adolescence or early adulthood, with follow-up based on the findings. Lung function tests are central to monitoring, and a blood test called VEGF-D can help; a normal result does not rule out LAM.
Will a TSC-related heart rhabdomyoma go away?
Most cardiac rhabdomyomas shrink substantially or disappear during the first two years of life. Treatment may be needed if a tumor blocks blood flow or causes dangerous abnormal heart rhythms; an mTOR medicine may be used, while surgery is uncommon.
How are facial angiofibromas treated in TSC?
Topical sirolimus, applied as a cream or gel, can reduce the size and redness of facial angiofibromas. Other skin lesions may be managed with laser treatment or minor surgery when they cause discomfort or cosmetic concerns.
Do retinal hamartomas require regular eye exams?
Retinal hamartomas are usually harmless and do not affect vision, but dilated eye exams help monitor for changes or rare complications. The exam schedule depends on the lesions and their stability, so it may not need to be every year.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.What is the current size of the largest kidney tumor (AML), and are there signs of active growth or other risk factors that suggest mTOR therapy?
  2. 2.Based on my (or my child's) age and sex, when should we schedule the first chest CT scan to screen for lung disease (LAM)?
  3. 3.How frequently should we be monitoring my kidney function (eGFR) and checking for protein in my urine?
  4. 4.Is a topical sirolimus cream or gel appropriate for these facial angiofibromas, and how long does it typically take to see an improvement?
  5. 5.Are there any retinal hamartomas present, and if so, how often do we need a dilated eye exam to ensure they aren't causing vision problems?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (31)
  1. 1

    Tuberous sclerosis complex.

    Islam MP, Roach ES

    Handbook of clinical neurology 2015; (132()):97-109.

    PMID: 26564073
  2. 2

    The importance of imaging in tuberous sclerosis complex (tsc) in children: Two cases.

    Dedushi K, Hyseni F, Musa J, et al.

    Radiology case reports 2022; (17(2)):399-403 doi:10.1016/j.radcr.2021.11.007.

    PMID: 34925673
  3. 3

    Renal angiomyolipoma in patients with tuberous sclerosis complex: findings from the TuberOus SClerosis registry to increase disease Awareness.

    Kingswood JC, Belousova E, Benedik MP, et al.

    Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 2019; (34(3)):502-508 doi:10.1093/ndt/gfy063.

    PMID: 29697822
  4. 4

    Renal manifestations of tuberous sclerosis complex: patients' and parents' knowledge and routines for renal follow-up - a questionnaire study.

    Cockerell I, Guenin M, Heimdal K, et al.

    BMC nephrology 2018; (19(1)):39 doi:10.1186/s12882-018-0835-3.

    PMID: 29439672
  5. 5

    Multicystic Kidney Disease in a Family With Tuberous Sclerosis Complex.

    Donald JS, Edmonstone C, Chan DL, et al.

    Nephrology (Carlton, Vic.) 2026; (31(3)):e70177 doi:10.1111/nep.70177.

    PMID: 41765377
  6. 6

    Kidneys in Children with Tuberous Sclerosis Complex-An Up-to-Date Review.

    Wabik AM, Pytlos J, Michalczewska A, Skrzypczyk P

    Journal of clinical medicine 2025; (14(21)) doi:10.3390/jcm14217805.

    PMID: 41227201
  7. 7

    Treatment of Renal Angiomyolipoma and Other Hamartomas in Patients with Tuberous Sclerosis Complex.

    Samuels JA

    Clinical journal of the American Society of Nephrology : CJASN 2017; (12(7)):1196-1202 doi:10.2215/CJN.08150816.

    PMID: 28302901
  8. 8

    Recommendations for imaging-based diagnosis and management of renal angiomyolipoma associated with tuberous sclerosis complex.

    Buj Pradilla MJ, Martí Ballesté T, Torra R, Villacampa Aubá F

    Clinical kidney journal 2017; (10(6)):728-737 doi:10.1093/ckj/sfx094.

    PMID: 29225800
  9. 9

    Spontaneous angiomyolipoma rupture: A case of hemorrhagic shock and urgent embolization.

    Awashra A, Sawaftah Z, Milhem F, et al.

    Radiology case reports 2024; (19(12)):6286-6291 doi:10.1016/j.radcr.2024.09.034.

    PMID: 39387028
  10. 10

    Review of the Tuberous Sclerosis Renal Guidelines from the 2012 Consensus Conference: Current Data and Future Study.

    Kingswood JC, Bissler JJ, Budde K, et al.

    Nephron 2016; (134(2)):51-58 doi:10.1159/000448293.

    PMID: 27504842
  11. 11

    Update on the Diagnosis and Management of Renal Angiomyolipoma.

    Flum AS, Hamoui N, Said MA, et al.

    The Journal of urology 2016; (195(4 Pt 1)):834-46.

    PMID: 26612197
  12. 12

    [Sporadic Lymphangioleiomyomatosis (sLAM) and Tuberous Sclerosis Complex (TSC) - Pulmonary Manifestations].

    Brakemeier S, Grohé C, Bachmann F, Budde K

    Pneumologie (Stuttgart, Germany) 2017; (71(2)):86-95 doi:10.1055/s-0042-111522.

    PMID: 27585353
  13. 13

    Women with TSC: Relationship between Clinical, Lung Function and Radiological Features in a Genotyped Population Investigated for Lymphangioleiomyomatosis.

    Di Marco F, Terraneo S, Imeri G, et al.

    PloS one 2016; (11(5)):e0155331 doi:10.1371/journal.pone.0155331.

    PMID: 27171001
  14. 14

    Lymphangioleiomyomatosis: a clinical review.

    O'Mahony AM, Lynn E, Murphy DJ, et al.

    Breathe (Sheffield, England) 2020; (16(2)):200007 doi:10.1183/20734735.0007-2020.

    PMID: 33304400
  15. 15

    Serum vascular endothelial growth factor-D as a diagnostic and therapeutic biomarker for lymphangioleiomyomatosis.

    Hirose M, Matsumuro A, Arai T, et al.

    PloS one 2019; (14(2)):e0212776 doi:10.1371/journal.pone.0212776.

    PMID: 30818375
  16. 16

    A 24-year-Old woman with recurrent pneumothoraces.

    Greenberg DJ, Sah A, Chopra A, Madisi N

    Respiratory medicine case reports 2024; (49()):102015 doi:10.1016/j.rmcr.2024.102015.

    PMID: 38596619
  17. 17

    Tuberous sclerosis complex for the pulmonologist.

    Rebaine Y, Nasser M, Girerd B, et al.

    European respiratory review : an official journal of the European Respiratory Society 2021; (30(161)) doi:10.1183/16000617.0348-2020.

    PMID: 34348978
  18. 18

    Lymphangioleiomyomatosis in patients with tuberous sclerosis: a national centre audit.

    Johnson J, Somerfield W, Johnson SR

    Orphanet journal of rare diseases 2024; (19(1)):137 doi:10.1186/s13023-024-03115-y.

    PMID: 38532450
  19. 19

    Characteristics and Outcomes of Fetal Cardiac Rhabdomyoma With or Without mTOR Inhibitors, a Systematic Review and Meta-Analysis.

    Mustafa HJ, Javinani A, Morning ML, et al.

    Prenatal diagnosis 2024; (44(10)):1251-1267 doi:10.1002/pd.6640.

    PMID: 39164800
  20. 20

    Cardiac Rhabdomyoma in Adult.

    Ghosh S, Milunski MR

    Cureus 2021; (13(4)):e14565 doi:10.7759/cureus.14565.

    PMID: 34026381
  21. 21

    Prenatally Diagnosed Cardiac Tumors and Tuberous Sclerosis Complex: A Single-Center Experience.

    Bakoš M, Jelinek D, Ćorić Ljoka A, et al.

    Children (Basel, Switzerland) 2025; (12(1)) doi:10.3390/children12010094.

    PMID: 39857925
  22. 22

    Everolimus and sirolimus in the treatment of cardiac rhabdomyomas in neonates.

    Hurtado-Sierra D, Ramos Garzón JX, Romero-Guevara SL, et al.

    Pediatric research 2025; doi:10.1038/s41390-025-04043-8.

    PMID: 40287604
  23. 23

    Cardiac rhabdomyomas: clinical progression, efficacy and safety of everolimus treatment.

    Yıldırım S, Aypar E, Aydın B, et al.

    The Turkish journal of pediatrics 2023; (65(3)):479-488.

    PMID: 37395967
  24. 24

    Cardiac Rhabdomyomas Presenting with Critical Cardiac Obstruction in Neonates and Infants: Treatment Strategies and Outcome, A Single-Center Experience.

    Ng LY, McGuinness J, Prendiville T, et al.

    Pediatric cardiology 2024; (45(5)):1132-1141 doi:10.1007/s00246-024-03420-0.

    PMID: 38480570
  25. 25

    Efficacy and Safety of Topical Sirolimus Therapy for Facial Angiofibromas in the Tuberous Sclerosis Complex : A Randomized Clinical Trial.

    Wataya-Kaneda M, Nakamura A, Tanaka M, et al.

    JAMA dermatology 2017; (153(1)):39-48 doi:10.1001/jamadermatol.2016.3545.

    PMID: 27837201
  26. 26

    Long-term treatment of cutaneous manifestations of tuberous sclerosis complex with topical 1% sirolimus cream: A prospective study of 25 patients.

    Malissen N, Vergely L, Simon M, et al.

    Journal of the American Academy of Dermatology 2017; (77(3)):464-472.e3 doi:10.1016/j.jaad.2017.04.005.

    PMID: 28502378
  27. 27

    Dermatological manifestations of tuberous sclerosis complex (TSC).

    Ebrahimi-Fakhari D, Meyer S, Vogt T, et al.

    Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG 2017; (15(7)):695-700 doi:10.1111/ddg.13264.

    PMID: 28598544
  28. 28

    Cutaneous manifestations of tuberous sclerosis complex and the paediatrician's role.

    Cardis MA, DeKlotz CMC

    Archives of disease in childhood 2017; (102(9)):858-863 doi:10.1136/archdischild-2016-312001.

    PMID: 28351834
  29. 29

    Ophthalmic manifestations of tuberous sclerosis: a review.

    Hodgson N, Kinori M, Goldbaum MH, Robbins SL

    Clinical & experimental ophthalmology 2017; (45(1)):81-86 doi:10.1111/ceo.12806.

    PMID: 27447981
  30. 30

    Updated International Tuberous Sclerosis Complex Diagnostic Criteria and Surveillance and Management Recommendations.

    Northrup H, Aronow ME, Bebin EM, et al.

    Pediatric neurology 2021; (123()):50-66 doi:10.1016/j.pediatrneurol.2021.07.011.

    PMID: 34399110
  31. 31

    Neuro-ophthalmological manifestations of tuberous sclerosis: current perspectives.

    Wan MJ, Chan KL, Jastrzembski BG, Ali A

    Eye and brain 2019; (11()):13-23 doi:10.2147/EB.S186306.

    PMID: 31417327

This page is for informational purposes only and does not constitute medical advice. A TSC care team should tailor screening and treatment to the patient's age, sex, symptoms, and test results.

Get notified when new evidence is published on Tuberous sclerosis complex.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.